Delving into the Latest Updates on R-Tech Ueno, Ltd. with Synapse

Overview

This study is a multicenter trial performed in Japan, consisting of a comparative study period and a continuous administration period.
Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study in patients with retinitis pigmentosa.
The safety of same eye drops will also be examined in 52 weeks continuous administration period, in all the patients who completed the comparative study period.

Start Date01 Mar 2013

Sponsor / Collaborator

R-Tech Ueno, Ltd.

JPRN-jRCT2080222033 / Unknown statusPhase 3

Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period

Start Date28 Feb 2013

Sponsor / Collaborator

R-Tech Ueno, Ltd.

100 Clinical Results associated with R-Tech Ueno, Ltd.

Login to view more data

0 Patents (Medical) associated with R-Tech Ueno, Ltd.

Login to view more data

4

Literatures (Medical) associated with R-Tech Ueno, Ltd.

01 Dec 2016·Investigative Opthalmology & Visual ScienceQ2 · MEDICINE

Long-Term Protection of Genetically Ablated Rabbit Retinal Degeneration by Sustained Transscleral Unoprostone Delivery

Q2 · MEDICINE

ArticleOA

Author: Nishizawa, Matsuhiko ; Liu, Junjun ; Terasaki, Hiroko ; Abe, Toshiaki ; Nakazawa, Toru ; Mashima, Yukihiko ; Osumi, Noriko ; Koyanagi, Eri ; Katsuyama, Aya ; Kondo, Mineo ; Kaji, Hirokazu ; Izumida, Yasuko ; Nagai, Nobuhiro

PurposeTo evaluate the long-term protective effects of transscleral unoprostone (UNO) against retinal degeneration in transgenic (Tg) rabbits (Pro347Leu rhodopsin mutation).MethodsThe UNO release devices (URDs) were implanted into the sclerae of Tg rabbits and ERG, optical coherence tomography (OCT), and ophthalmic examinations were conducted for 40 weeks. Unoprostone metabolites in retina, choroid/RPE, aqueous humor, and plasma from wild-type (Wt) rabbits were measured using liquid chromatography-tandem mass spectrometry. In situ hybridization and immunohistochemistry evaluated the retinal distribution of big potassium (BK) channels, and RT-PCR evaluated the expressions of BK channels and m-opsin at 1 week after URD treatment.ResultsThe URD released UNO at a rate of 10.2 ±1.0 μg/d, and the release rate and amount of UNO decreased during 32 weeks. Higher ERG amplitudes were observed in the URD-treated Tg rabbits compared with the placebo-URD, or nontreated controls. At 24 weeks after implantation into the URD-treated Tg rabbits, OCT images showed preservation of retinal thickness, and histologic examinations (44 weeks) showed greater thickness of outer nuclear layers. Unoprostone was detected in the retina, choroid, and plasma of Wt rabbits. Retina/plasma ratio of UNO levels were 38.0 vs. 0.68 ng UNO*hour/mL in the URD-treated group versus control (topical UNO), respectively. Big potassium channels were observed in cone, cone ON-bipolar, and rod bipolar cells. Reverse-transcriptase PCR demonstrated BK channels and m-opsins increased in URD-treated eyes.ConclusionsIn Tg rabbits, URD use slowed the decline of retinal function for more than 32 weeks, and therefore provides a promising tool for long-term treatment of RP.

Molecular Vision

Blockade of vascular adhesion protein-1 attenuates choroidal neovascularization.

Author: Kousuke Noda ; Yoko Ozawa ; Susumu Ishida ; Nami Yoshikawa ; Yukihiko Mashima ; Kazuo Tsubota

Purpose: Vascular adhesion protein (VAP)-1 is an adhesion molecule elucidated as a mediator of the leukocyte recruitment cascade. The purpose of this study was to investigate the role of VAP-1 in ocular inflammatory neovascularization using a mouse laser-induced choroidal neovascularization (CNV) model. Methods: CNV was induced with 532 nm laser irradiation in C57BL/6 mice, and production of VAP-1 protein in the retinal pigment epithelium (RPE) choroid during CNV formation was examined. CNV animals were treated with the specific VAP-1 inhibitor U-V002 or vehicle solution, and the volume of CNV tissue was evaluated with volumetric measurements. Macrophage infiltration into the CNV lesions was evaluated using two different techniques, flatmount staining and real-time polymerase chain reaction (PCR) for F4/80. The protein levels of intercellular adhesion molecule (ICAM)-1, monocyte chemoattractant protein (MCP)-1, P-selectin, and vascular endothelial growth factor (VEGF) in the RPE-choroid were measured with enzyme-linked immunosorbent assay (ELISA). Results: VAP-1 inhibition significantly suppressed CNV formation in a dose-dependent manner and reduced macrophage infiltration into CNV lesions. Furthermore, VAP-1 blockade decreased the expression of ICAM-1 and MCP-1, both of which play a pivotal role in macrophage recruitment. Conclusions: Our data suggest VAP-1 has an important role during ocular inflammatory neovascularization through leukocyte recruitment. VAP-1 inhibition may be a novel and potent therapeutic strategy in treating CNV formation.

Igaku to Yakugaku

Neuroprotective effects of the BK channel activator isopropyl unoprostone during and after post-ischemic reperfusion

Author: Mashima, Yukihiko ; Tabuchi, Reiko ; Yoshikawa, Nami ; Inoue, Ryo ; Kawai, Yousuke ; Hanada, Keizou

Here, the authors examined a neuroprotective effect of iso-Pr unoprostone in vitro using a rat model of local ischemic reperfusion.The results demonstrated the neuroprotective effect of iso-Pr unoprostone for post-ischemic reperfusion.

100 Deals associated with R-Tech Ueno, Ltd.

Login to view more data

100 Translational Medicine associated with R-Tech Ueno, Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Unoprostone Isopropyl ( PTGFR )	Retinitis Pigmentosa More	Discontinued
Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.) ( albumin )	Dry Eye Syndromes More	Pending